Genedrive Share Discussion Threads

[z1co] 06/9/2024 13:00

Batti

STOP posting LIES

[z1co] 06/9/2024 12:59

The Genedrive® MT-RNR1 test received conditional recommendation from the UK's National Institute for Health and Care Excellence ("NICE") in March 2023, enabling its use in the NHS whilst further evidence is generated. Plans for generating the required further evidence are underway, with the goal of enabling transition from conditional to full recommendation by NICE, which in turn is expected to facilitate funding for the test at a national level.

[z1co] 06/9/2024 12:58

The CYP2C19-ID Test has a full recommendation for the UK , so it will be rolled out to
the NHS hospitals in the UK.

As you know it was only approved on 31st July so it's only been 6 weeks and has already won ONE major hospital , more contracts will be announced over the coming weeks/months.

[batiatus] 06/9/2024 12:45

Yes, the company raised cash a few months ago, but their cash burn is £400-600K a month.

Doesn't take rocket science to figure out the money will quickly run out.

So there you go! Placing coming!

[z1co] 06/9/2024 12:32

In March 2023, the Genedrive® MT-RNR1-ID Kit received a recommendation for use in the UK by the National Institute for Health and Care Excellence ("NICE") under its Early Value Assessment Programme ("EVA"). The EVA was introduced to allow rapid assessment of digital products, devices and diagnostics for clinical effectiveness and value for money, so that the NHS and patients can benefit from these promising technologies sooner. The recommendation is conditional on further evidence being generated and the Company is a partner with clinical colleagues at Manchester University NHS Foundation Trust ("MFT") who have recently applied for funding to address the NICE EVA evidence generation recommendations, which are required for progressing the NICE conditional recommendation into a full recommendation at the earliest opportunity.

[z1co] 06/9/2024 12:31

This will help you:

The NIHR i4i & OLS Real World Evidence Programme is intended to address each eligible EVA, is being led by Office for Life Sciences ("OLS") as part of the UK Government's Life Sciences Vision and is backed by £10m of government funding and is expected to commence in October 2024.

[z1co] 06/9/2024 12:31

Batti gone quiet again ' that's what the LIARS usually do.

[z1co] 06/9/2024 12:26

Another LIE posted by Batti

The company only recently raised £6m gross

[z1co] 06/9/2024 12:22

What have you got to say about your LIES???

[batiatus] 06/9/2024 12:11

I expect placing news before a sales contract news, if any!

[z1co] 06/9/2024 11:36

Batti

You LIAR you still HAVE NOT answered my questions.

[batiatus] 06/9/2024 11:33

GEX looking more exciting and closer to important news.

GDR had too many chances and the BOD failed to deliver them.

Share price went from £2 high to now 2p

[themachine2] 06/9/2024 11:21

This bit is very important for this small company:

"with the goal of enabling transition from conditional to full recommendation by NICE, which in turn is expected to facilitate funding for the test at a national level."

[themachine2] 06/9/2024 11:16

zico

Good factual info

Hopefully that will keep Batiatus from posting porkies on this thread

[z1co] 06/9/2024 10:45

In March 2023, the Genedrive® MT-RNR1-ID Kit received a recommendation for use in the UK by the National Institute for Health and Care Excellence ("NICE") under its Early Value Assessment Programme ("EVA"). The EVA was introduced to allow rapid assessment of digital products, devices and diagnostics for clinical effectiveness and value for money, so that the NHS and patients can benefit from these promising technologies sooner. The recommendation is conditional on further evidence being generated and the Company is a partner with clinical colleagues at Manchester University NHS Foundation Trust ("MFT") who have recently applied for funding to address the NICE EVA evidence generation recommendations, which are required for progressing the NICE conditional recommendation into a full recommendation at the earliest opportunity.

[z1co] 06/9/2024 10:44

You gone quiet , i thought you would

Lets posts some FACTS:

The Genedrive® MT-RNR1 test received conditional recommendation from the UK's National Institute for Health and Care Excellence ("NICE") in March 2023, enabling its use in the NHS whilst further evidence is generated. Plans for generating the required further evidence are underway, with the goal of enabling transition from conditional to full recommendation by NICE, which in turn is expected to facilitate funding for the test at a national level.

[z1co] 06/9/2024 10:34

Batti

You THICKO what are you on about July ?

Are you making reference to CYP2C19 or MT-RNR1 ?

You are very confused , been spending too much time posting LIES